HER2-Specific CAR T Cell Therapy for Pediatric CNS Tumors

Phase 1, open-label trial of BrainChild-01 in central nervous system tumor (2 arms), sponsored by Seattle Children's. Primary endpoints: Safety defined by adverse events at 6 months and Feasibility of CAR T cell production and administration at 28 days. Started Jul 2018; status: active, not recruiting.